GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model

Transl Neurodegener. 2024 Sep 20;13(1):49. doi: 10.1186/s40035-024-00441-w.

Didio Alberto Ortiz^#¹, Nuria Peregrín^#¹, Miguel Valencia^{2

3

4}, Rodrigo Vinueza-Gavilanes^{1

4}, Elisa Marín-Ordovas⁵, Roberto Ferrero^{1

4}, María Jesús Nicolás^{2

4}, Gloria González-Aseguinolaza^{1

4}, Montserrat Arrasate^#^{6

7

8

9

10}, Tomás Aragón^#^{11

12}

¹ DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
² Biomedical Engineering Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
³ Institute of Data Science and Artificial Intelligence (DATAI), University of Navarra, Pamplona, Spain.
⁴ Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
⁵ Neuroimmunology Department, Multiple Sclerosis Center of Catalonia (Cemcat), Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
⁶ DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. [email protected].
⁷ Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [email protected].
⁸ School of Medicine, University of Navarra, Pamplona, Spain. [email protected].
⁹ Brain Lab, Biobizkaia Health Research Institute, Barakaldo, Spain. [email protected].
¹⁰ Ikerbasque, Basque Foundation for Science, Bilbao, Spain. [email protected].
¹¹ DNA and RNA Medicine Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain. [email protected].
¹² Navarra Institute for Health Research (IdiSNA), Pamplona, Spain. [email protected].

^# Contributed equally.

No abstract available

Publication types